Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: The FAST-MI registry

Archives of Cardiovascular Diseases

Volumn 105, Issue 6-7, 2012, Pages 347-354

  Puymirat, Étienne ^a   Aissaoui, Nadia ^a   Silvain, Johanne ^b   Bonello, Laurent ^c   Cuisset, Thomas ^d   Motreff, Pascal ^e   Bataille, Vincent ^f   Durand, Eric ^a   Cottin, Yves ^g   Simon, Tabassome ^h   Danchin, Nicolas ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d TIMONE HOSPITAL   (France)

^e SERVICE DE RHUMATOLOGIE   (France)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g DIJON UNIVERSITY HOSPITAL   (France)

^h HÔPITAL SAINT ANTOINE   (France)

Author keywords

Acute myocardial infarction; Bleeding; Low molecular weight heparin; Unfractionated heparin

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CARDIAC PATIENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE REGISTRY; DRUG FATALITY; FEMALE; FRANCE; HAZARD RATIO; HEART DEATH; HEART REINFARCTION; HUMAN; INTENSIVE CARE UNIT; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; RETROPERITONEAL HEMORRHAGE; RISK; STROKE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; FIBRINOLYTIC AGENTS; FRANCE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864138852     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2012.04.002     Document Type: Article

References (24)

1. E.M. Antman, M. Cohen, and C. McCabe Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE Eur Heart J 23 2002 308 314 (Pubitemid 35204217)
2. E.M. Antman, C.H. McCabe, and E.P. Gurfinkel Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial Circulation 100 1999 1593 1601 (Pubitemid 29477267)
3. E.M. Antman, D.A. Morrow, and C.H. McCabe Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354 2006 1477 1488
4. M. Cohen, C. Demers, and E.P. Gurfinkel Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events Am J Cardiol 82 1998 19L 24L
5. M. Cohen, P. Theroux, and S. Borzak Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The antithrombotic combination using tirofiban and enoxaparin Am Heart J 144 2002 470 477
6. D.H. Fitchett, A. Langer, and P.W. Armstrong Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial Am Heart J 151 2006 373 379 (Pubitemid 43144741)
7. K.W. Mahaffey, and J.J. Ferguson Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial Am Heart J 149 2005 S81 S90
8. U. Zeymer, A. Gitt, and C. Junger Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST-elevations in clinical practice Am J Cardiol 98 2006 19 22 (Pubitemid 43902675)
9. J. Silvain, F. Beygui, and O. Barthelemy Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis BMJ 344 2012 e553
10. G. Montalescot, U. Zeymer, and J. Silvain Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial Lancet 378 2011 693 703
11. J.P. Cambou, T. Simon, and G. Mulak The French registry of Acute ST-elevation or non-ST-elevation Myocardial Infarction (FAST-MI): study design and baseline characteristics Arch Mal Coeur Vaiss 100 2007 524 534 (Pubitemid 47234424)
12. T. Simon, P.G. Steg, and M. Gilard Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry Circulation 123 2011 474 482
13. A.K. Rao, C. Pratt, and A. Berke Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11 (Pubitemid 18029027)
14. E. Puymirat, N. Aissaoui, and J.P. Collet Comparison of bleeding complications and one-year survival of low-molecular-weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry Int J Cardiol 2011 [PMID: 22078393]
15. J.W. Suh, R. Mehran, and B.E. Claessen Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial J Am Coll Cardiol 58 2011 1750 1756
16. K. Barakat, P. Wilkinson, and A. Deaner How should age affect management of acute myocardial infarction. A prospective cohort study Lancet 353 1999 955 959 (Pubitemid 29132603)
17. S. De Servi, C. Cavallini, and A. Dellavalle Non-ST-elevation acute coronary syndrome in the elderly: treatment strategies and 30-day outcome Am Heart J 147 2004 830 836 (Pubitemid 38880993)
18. C.N. Shahi, S.S. Rathore, and Y. Wang Quality of care among elderly patients hospitalized with unstable angina Am Heart J 142 2001 263 270 (Pubitemid 32706284)
19. R.M. Califf, J.L. Petersen, and V. Hasselblad A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes Am Heart J 149 2005 S91 S99
20. M. Cohen The role of low-molecular-weight heparin in the management of acute coronary syndromes J Am Coll Cardiol 41 2003 55S 61S (Pubitemid 36223348)
21. M. Cohen, C. Demers, and E.P. Gurfinkel A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group N Engl J Med 337 1997 447 452 (Pubitemid 27333045)
22. G.C. Wong, R.P. Giugliano, and E.M. Antman Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention JAMA 289 2003 331 342 (Pubitemid 36090107)
23. F.G. Kushner, M. Hand, and S.C. Smith Jr. 2009 Focused Updates: ACC/AHA guidelines for the management of patients with ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
24. W. Wijns, P. Kolh, and N. Danchin Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555